Relative lymphocyte count (RLC) and relative eosinophil count (REC) were also evaluated by the same group in advanced melanoma patients receiving chemotherapy (n = 116) or anti-CTLA-4 therapy (n = 128) [87]. The gene discussed is CTLA4; the disease is melanoma.